Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer

Reza Shahbazi, Elif Asik, Nermin Kahraman, Mustafa Turk, Bulent Ozpolat, Kezban Ulubayram

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Aim: In this study, we aimed to therapeutically target eukaryotic elongation factor 2 kinase (eEF-2K) in an in vivo triple-negative breast cancer (TNBC) tumor model. Materials & methods: We synthesized a highly monodisperse nanoformulation using polyethylenimine-modified gold nanoparticles (AuNP-PEI) as siRNA delivery vehicle and evaluated gene downregulation. Results: We found that AuNP-PEI/eEF-2K nanoformulation was highly effective for in vitro and in vivo gene downregulation and showed remarkable antitumor efficacy that was associated with eEF-2K knockdown, inhibition of Src and MAPK-ERK signaling pathways in a TNBC orthotopic tumor model. Conclusion: Our study suggests that eEF-2K plays an important role in TNBC tumorigenesis and its inhibition by AuNP-PEI/eEF-2K siRNA-based nanotherapeutics may be a potential therapeutic strategy for TNBC.

Original languageEnglish (US)
Pages (from-to)1961-1973
Number of pages13
Issue number16
StatePublished - Aug 2017


  • eEF-2K siRNA
  • eEF2K
  • eukaryotic elongation factor 2 kinase
  • nanotherapeutics
  • PEI-modified gold nanoparticles
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)


Dive into the research topics of 'Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this